We’re Fighting for Nebraskan’s Rights
The Invokana (Invokamet) lawsuit alleges that manufacturers and marketers of SGLT2 inhibitors (such as Johnson & Johnson, Janssen Pharmaceuticals Inc., AstraZeneca & Boehringer Ingelheim) failed to warn patients and physicians of the increased risks of kidney failure, myocardial infarction (heart attacks), other cardiovascular issues and ketoacidosis. The lawsuits provide that if the manufacturers and marketers had properly warned of the risks, patients would have been prescribed and taken a substitute medication for their diabetes, and certainly would have had their health monitored on a more routine basis for potential signs of heart issues, renal impairment, and high level of ketones.
The following brans name prescription medications are being investigated
Brand Name | Active Ingredients
Invokana (Invokamet) | Canagliflozin
Invokamet | Canagliflozin and Metformin
Farxiga | Dapagliflozin
Xigduo XR | Dapagliflozin and Metformin extended-release
Jardiance | Empagliflozin
Glyxambi | Empagliflozin and Linagliptin
Invokana (Invokamet) Side Effects, Problems and Risks
A report by the Institute of Safe Medication Practices (ISMP) mentioned potential concerns regarding a potential link between Invokana and kidney damage after reviewing adverse event reports submitted to the FDA during the drug’s first year on the market after its approval in 2013.
“… early signals for a new kind of diabetes drug, canagliflozin (INVOKANA) raise questions about whether enough is known about this agent to be assured that its benefits outweigh its risks.”
They identified more than 400 incidents that implied signs of renal toxicity, including:
- Urinary tract infection
- Kidney failure
- Impaired renal function
- Kidney stones
The FDA warned that SGLT2 inhibitor use might lead to ketoacidosis, a serious condition in which the body produces high levels of blood acids known as ketones that may require a patient to be hospitalized. According to the FDA:
The U.S. Food and Drug Administration (FDA) is warning that the type 2 diabetes medicines canagliflozin, dapagliflozin, and empagliflozin may lead to ketoacidosis, a serious condition where the body produces high levels of blood acids called ketones that may require hospitalization. We are continuing to investigate this safety issue and will determine whether changes are needed in the prescribing information for this class of drugs, called sodium-glucose cotransporter-2 (SGLT2) inhibitors.
Patients should pay close attention for any signs of ketoacidosis and seek medical attention immediately if they experience symptoms such as difficulty breathing, nausea, vomiting, abdominal pain, confusion, and unusual fatigue or sleepiness. Do not stop or change your diabetes medicines without first talking to your prescriber. Health care professionals should evaluate for the presence of acidosis, including ketoacidosis, in patients experiencing these signs or symptoms; discontinue SGLT2 inhibitors if acidosis is confirmed; and take appropriate measures to correct the acidosis and monitor sugar levels.
The investigations of Invokana are ongoing at this time.
Inserra and Kelley Fights Behalf of Nebraskan’s
Inserra and Kelley is participating in the fight against Janssen Pharmaceuticals and other related corporate entities. If you have been potentially injured by the use of Invokana (Invokamet), your statute of limitations may already have expired, or may expire in the very near future. Unfortunately, there is no way for us to tell you without reviewing the individual facts of your situation. The one thing we can absolutely state is that every day you wait to retain an attorney may be the last day you can bring a claim.
Inserra and Kelley believes in holding large corporations accountable when they do something wrong. We won’t back down from corporate legal teams, and we’ll do everything we can to protect your rights. Call us today at (402) 391-4000.
Other Invokana (Invokamet) News:
Perspective: SGLT2 inhibitors may predispose to ketoacidosis
SGLT2 Inhibitor Diabetes Drugs May Cause Ketoacidosis
FDA Issues Warning for Type 2 Diabetes Drugs